03293: Foundational Studies for Translating FGFR Inhibition in Canine Osteosarcoma
Grant Status: Open
One Health: Yes
Abstract
This study aims to identify splicing isoforms and genomic mutations of fibroblast growth factor receptors (FGFRs), that are linked to the progression of osteosarcoma cells, with the goal of developing a preclinical platform for testing selective FGFR inhibitors. Specifically, the project will explore the relationship between alternative splicing isoforms, genetic mutations, and aggressive behavior by measuring cell invasiveness. Then, the optimized cell model will be used to test FGFR inhibitors, evaluating how alternative splicing and the genomic landscape influence cell sensitivity and primary resistance to targeted therapies. Additionally, functional tests will be conducted to either reduce or enhance the function of specific splicing forms to gain a deeper understanding of the underlying mechanisms.
The significance of this study lies in its potential to adapt new chemotherapy types, already used in human oncology, for veterinary clinical practice, opening the door to clinical studies in dogs. Additionally, it establishes a preclinical model for personalized medicine in dogs, taking into account how the surrounding cell environment affects FGFR splicing and cell invasion. The findings could inform clinical trials by uncovering possible reasons for treatment challenges, highlighting the need to evaluate oncogenic FGFR transcripts and genetic mutations when selecting patients.
Publication(s)
None at this time.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.
